Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | STAT1 | P42224 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | NPY1R | P25929 | 1/20 | 0.63 |
| ▸ | NPY2R | P49146 | 1/20 | 0.63 |
| ▸ | DHODH | Q02127 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17982140 | 0.86 | GAA (0.58) | GAANPSR1SMN1; SMN2LMNASTAT1 | |
| SCHEMBL17963146 | 0.85 | GAA (0.67) | GAANPSR1SMN1; SMN2LMNASTAT1 | |
| SCHEMBL583369 | 0.85 | GAA (0.70) | GAANPSR1SMN1; SMN2LMNASTAT1 | |
| SCHEMBL3600779 | 0.81 | SMN1; SMN2 (0.53) | GAANPSR1SMN1; SMN2LMNASTAT1 | |
| SCHEMBL31023675 | 0.81 | GAA (0.65) | GAANPSR1SMN1; SMN2LMNASTAT1 | |
| SCHEMBL17963068 | 0.80 | GAA (0.61) | GAANPSR1SMN1; SMN2LMNASTAT1 | |
| SCHEMBL20418858 | 0.80 | NPSR1 (1.00) | GAANPSR1SMN1; SMN2LMNASTAT1 | |
| SCHEMBL6293909 | 0.80 | LMNA (1.00) | GAANPSR1SMN1; SMN2LMNASTAT1 | |
| SCHEMBL21874491 | 0.80 | KDM4E (0.83) | GAANPSR1SMN1; SMN2LMNASTAT1 | |
| SCHEMBL20418823 | 0.79 | GAA (0.55) | GAANPSR1SMN1; SMN2LMNASTAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-26 | — | — | US | disclosed |
| WO-2016123392-A2 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-08-04 | — | — | WO | disclosed |
| EP-2124944-B1 | Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LAB LTD (IN) | 2012-02-15 | — | — | EP | disclosed |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
| US-7915286-B2 | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-29 | — | — | US | disclosed |
| EP-2124943-A1 | PYRAZOLO [3, 4-B]PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008111009-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | NR3C1, NR3C2, GRK3 | GAA 2062/4885NPSR1 679/4885SMN1; SMN2 4568/4885 |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | NR3C1, NR3C2, GRK3 | GAA 1401/4885NPSR1 408/4885SMN1; SMN2 4638/4885 |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3B, PDE4B | GAA 815/4885NPSR1 2185/4885SMN1; SMN2 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.